Press Releases

KemPharm® is a clinical stage, specialty pharmaceutical company engaged in the development and discovery of proprietary prodrugs that are designed to be improved versions of widely prescribed and FDA approved products.

Press Releases

News Releases

Date Title and Summary
Toggle Summary KemPharm Submits NDA for KP201/APAP and Requests Priority Review From the FDA
If Approved, KP201/APAP May be the First Immediate Release Hydrocodone Combination Product Candidate for the Treatment of Acute Pain Designed to Address Opioid Abuse and Misuse CORALVILLE, Iowa , Dec. 15, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), today announced that it has submitted a
Toggle Summary KemPharm, Inc. Reports Q3 2015 Results
Conference Call and Live Audio Webcast Scheduled for Today at 4:30 p.m. ET Recent Clinical Development Highlights: Completed Human Abuse Liability Program for KP201/APAP , KemPharm's prodrug of hydrocodone (KP201), formulated in combination with acetaminophen (APAP) Reported positive results from
Toggle Summary KemPharm, Inc. Completes Human Abuse Liability Program for KP201/APAP
Positive Results From Second Intranasal Human Abuse Liability Clinical Trial Reaffirm Properties of KP201/APAP Conference Call and Live Audio Webcast Scheduled for Today at 5:00 p.m. ET CORALVILLE, Iowa , Oct. 21, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc.
Toggle Summary KemPharm Enhances U.S. and Global Intellectual Property Estate
KemPharm Receives Patent From the USPTO for Novel Prodrug of Methylphenidate, KP415, Additional USPTO Patent Protection for KP201, and Multiple Ex-US Patents for KP511 and KP303 CORALVILLE, Iowa , Oct. 13, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty
Toggle Summary KemPharm Reports Positive Data Demonstrating Tamper-Resistant Properties of KP201/APAP
Results Indicate That Prodrug Design of KP201/APAP Significantly Hinders Traditional Means of Abuse, Including Extraction, Injection and Smoking CORALVILLE, Iowa , Sept. 30, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the
Toggle Summary KemPharm Expands Its Abuse-Deterrent Opioid Pipeline With New Acetaminophen-Free, Immediate Release Hydrocodone and Immediate Release Oxycodone Prodrug Product Candidates
Provides Updates on Clinical Development Pipeline and Anticipated NDA Filings CORALVILLE, Iowa , Sept. 24, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced today that
Toggle Summary KemPharm to Highlight the Potential of Prodrugs at the 9th Annual Pain & Migraine Therapeutics Summit
Presentation by Sven Guenther, Ph.D., KemPharm's EVP of Research & Development, to Showcase Prodrugs and the Clinical Progress of KP201/APAP and KP511 CORALVILLE, Iowa , Sept. 23, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in
Toggle Summary KemPharm Data to be Presented at PAINWeek 2015
Posters Highlight Data on Opioid Abuse Prevalence, and the Advantages of Prodrugs and KP201/APAP in Preventing Abuse and Misuse CORALVILLE, Iowa , Sept. 8, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and
Toggle Summary KemPharm, Inc. Announces Positive Data From Intranasal Human Abuse Liability Study of KP201/APAP; Reports Q2 2015 Results
Results from First of Two Intranasal Human Abuse Liability Clinical Studies Indicate KP201 Exhibits Significantly Lower Exposure to Hydrocodone When Administered Intranasally Conference Call and Live Audio Webcast Scheduled for Today at 4:30 p.m. ET Recent Clinical Development Highlights: Reports
Toggle Summary KemPharm, Inc. Announces Changes to Senior Leadership to Target Strategic Opportunities
Rusty Johnson Named as Newly Created Chief Business Officer; LaDuane Clifton Appointed as Chief Financial Officer CORALVILLE, Iowa , June 25, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of
Toggle Summary KemPharm, Inc. Reports Positive Data From Oral Human Abuse Liability Clinical Trial of KP201/APAP
Company to Host Conference Call and Live Audio Webcast Today at 8:30 a.m. ET CORALVILLE, Iowa , June 11, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced
Toggle Summary KemPharm, Inc. Reports Q1 2015 Results
Conference Call and Live Audio Webcast Scheduled for Today at 4:30 p.m. ET Recent Highlights: Completed pre-NDA meeting for KP201/APAP with FDA on May 20, 2015 Initial public offering closed on April 21, 2015 Appointed David M. Tierney to Board of Directors on March 3, 2015 Appointed Tracy M.
Toggle Summary KemPharm Completes Pre-NDA Meeting With FDA for KP201/APAP
Company Remains on Track for NDA Submission in Second Half of 2015 CORALVILLE, Iowa , May 21, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced today that the Company
Toggle Summary KemPharm's KP201/APAP Featured at the 2015 Abuse Deterrent Formulations Summit
KemPharm's Executive Vice President of R&D, Sven Guenther, Ph.D., to Discuss the Potential of Prodrug Technologies as a Deterrent to Opioid Tampering and Abuse CORALVILLE, Iowa , May 19, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq:KMPH), a clinical-stage specialty pharmaceutical company
Toggle Summary KemPharm Announces Pricing of Initial Public Offering
CORALVILLE, Iowa , April 15, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc. , a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary new molecular entity (NME) prodrugs, announced today the pricing of its initial public offering of 5,090,909 shares of its
Toggle Summary KemPharm, Inc. Appoints David S. Tierney, MD to Board of Directors
Coralville, IA – March 10, 2015 – KemPharm, Inc., a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary new molecular entity (NME) prodrugs, announced today the appointment of David S. Tierney, M.D. to its Board of Directors. Dr.
Toggle Summary KemPharm, Inc. Appoints Tracy M. Woody as Chief Commercial Officer
20-Year Pharmaceutical Sales & Marketing Executive to Spearhead Commercialization Strategy for KemPharm's NME Prodrug Pipeline, including KP201/APAP Coralville, IA – March 4, 2015 – KemPharm, Inc., a clinical-stage specialty pharmaceutical company engaged in the discovery and development of
Toggle Summary KemPharm, Inc. Completes Pre-IND Meeting with FDA for NME Prodrug of Hydromorphone, KP511
Coralville, IA – December 9, 2014 – KemPharm, Inc., a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary new molecular entity (NME) prodrugs, announced today that it had a pre-investigational new drug (pre-IND) meeting with the U.S.
Toggle Summary KemPharm, Inc. Receives Notice of Allowance for NME Prodrug of Methylphenidate, KP415
KP415 is Designed as an Abuse-Deterrent, Controlled Release Prodrug of Methylphenidate for the Treatment of ADHD Coralville, IA – December 5, 2014 – KemPharm, Inc., a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary new molecular entity (NME)
Toggle Summary KemPharm, Inc. Receives Patent from the USPTO for Novel Prodrug of Hydromorphone, KP511
KemPharm's Intellectual Property Estate Now Includes Composition of Matter Patents for Two Ligand Activated Technology (LAT) Opioid Produgs – KP511 and KP201 Coralville, IA – September 30, 2014 – KemPharm, Inc., a clinical-stage specialty pharmaceutical company engaged in the discovery and